Spero Therapeutics AI Stock Analysis
Want to see SPRO full AI Analyst Report?
Spero Therapeutics (SPRO) AI Stock Analysis
Spero Therapeutics
(NASDAQ:SPRO)
The score is held down primarily by weak financial performance (ongoing cash burn, volatile revenue/earnings, and a deteriorated TTM equity/leverage profile) and bearish technicals (below key moving averages with negative MACD). These are partially offset by a stronger earnings-call outlook driven by non-dilutive financing that extends runway to 2H 2029 and key strategic milestones (Utebzi approval and the SP001 license), though execution and funding-repayment dependence remain notable risks.
Spero Therapeutics (SPRO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $50.92M
- Dividend Yield
- ―
- Average Volume (3M)
- 529.78K
- Price to Earnings (P/E)
- -1.8
- Beta (1Y)
- 1.71
- Revenue Growth
- 36.15%
- EPS Growth
- 38.57%
- Country
- US
- Employees
- 25
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Spero Therapeutics Business Overview & Revenue Model
Company Description
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases withi...
Spero Therapeutics Earnings Call Summary
The call conveyed a strategic positive shift: an important product approval (Utebzi), a high-value in-license (SP001) with a clear development plan in IgG4-RD, a non-dilutive $105M financing that extends runway into H2 2029, and a strengthened clinical leadership team. Offsetting these positives are an absence of current revenue (Q2 2026 revenue $0 vs $14.2M prior year), a wider net loss and increased loss per share, dependence on GSK royalty/milestone streams to service the financing, and SP001 remaining early-stage with a small planned Phase II. On balance, management’s actions materially de-risk near-term funding and position the company for an immunology strategy, but meaningful clinical and commercial execution risks remain.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Spero said the key near‑term financial and development guidance is anchored by a $105.0M nondilutive, nonrecourse royalty financing (special‑purpose subsidiary issued $105M senior secured notes, 10% annual interest, 9‑year maturity, principal & interest payable quarterly from GSK Utebzi milestones/royalties; after repayment Spero retains 35% of additional GSK proceeds) and an exclusive SP001 license with Innovent with an estimated $1.1B total contingent value; cash & cash equivalents were $50.8M as of June 30 (pre‑financing) and, together with the financing, are expected to fund the $35M nonrefundable Innovent upfront plus operating and capex into the second half of 2029 (cash runway updated to 2H‑2029). Operational milestones include a Phase II IgG4‑RD trial planned to begin in Q2‑2027 (open‑label, 6 monthly doses, two dosing arms, up to ~15 patients per arm, i.e., ~30 patients total) and Utebzi availability in the U.S. in 2H‑2026; reported Q2‑2026 P&L metrics were net loss $9.6M (diluted loss per share $0.16) vs $1.7M ($0.03) in Q2‑2025, revenue $0 (vs $14.2M), R&D $3.4M (vs $10.7M) and G&A $6.5M (vs $5.9M).
Spero Therapeutics Financial Statement Overview
Summary
Financials are constrained by persistent cash burn and unstable profitability. Income results are volatile with a sharp TTM revenue decline and a sizable TTM net loss with very negative margins, while cash flow is consistently negative (TTM FCF about -$40.4M). Balance sheet risk increased in the TTM snapshot with sharply thinner equity and much higher debt-to-equity versus prior years.
Income Statement
41NeutralBalance Sheet
56NeutralCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 39.92M | 59.62M | 47.98M | 103.78M | 48.58M | 3.07M |
| Gross Profit | 39.92M | 59.62M | -48.78M | 52.34M | 48.58M | 3.07M |
| EBITDA | 8.11M | 8.83M | -72.48M | 27.15M | -42.94M | -87.17M |
| Net Income | -29.51M | 8.57M | -68.57M | 22.81M | -46.41M | -89.76M |
Balance Sheet | ||||||
| Total Assets | 110.03M | 68.92M | 110.54M | 182.39M | 124.80M | 171.07M |
| Cash, Cash Equivalents and Short-Term Investments | 107.93M | 40.27M | 52.89M | 76.33M | 109.11M | 146.40M |
| Total Debt | 1.59M | 2.90M | 4.30M | 5.54M | 6.65M | 7.33M |
| Total Liabilities | 109.25M | 9.90M | 64.42M | 75.50M | 48.87M | 82.78M |
| Stockholders Equity | 781.00K | 59.02M | 46.12M | 106.89M | 75.93M | 88.29M |
Cash Flow | ||||||
| Free Cash Flow | -40.45M | -12.62M | -23.44M | -32.99M | -7.73M | -64.35M |
| Operating Cash Flow | -40.45M | -12.62M | -23.44M | -32.99M | -7.73M | -64.35M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 33.81M | 7.67M |
| Financing Cash Flow | 99.76M | 0 | 0 | 221.00K | -29.55M | 84.05M |
Spero Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SPRO, the sentiment is Negative. The current price of 0.83 is below the 20-day moving average (MA) of 1.03, below the 50-day MA of 1.11, and below the 200-day MA of 1.89, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 27.03 is Positive, neither overbought nor oversold. The STOCH value of 5.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SPRO.
Spero Therapeutics Risk Analysis
Spero Therapeutics disclosed 65 risk factors in its most recent earnings report. Spero Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksSpero Therapeutics Peers Comparison
Overall Rating
INO55Neutral
SPRO47Neutral
MCRB44Neutral
PDSB44Neutral
COCP43Neutral
NNVC36Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 55Neutral | $305.31M | -2.12 | -9999.00% | ― | 63.93% | 68.94% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $50.92M | -1.78 | -75.22% | ― | 36.15% | 38.57% | |
| 44Neutral | $14.68M | -0.29 | -148.34% | ― | 505.41% | -889.29% | |
| 44Neutral | $82.33M | -1.40 | -559.99% | ― | ― | 32.24% | |
| 43Neutral | $18.82M | -1.21 | -320.01% | ― | ― | 17.71% | |
| 36Underperform | $30.41M | -2.19 | -137.90% | ― | ― | -5.19% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SPRO | Spero Therapeutics | 0.83 | -1.48 | -64.24% | |
| INO | Inovio Pharmaceuticals | 1.71 | -0.05 | -2.84% | |
| NNVC | NanoViricides Inc | 1.17 | -0.10 | -7.87% | |
| MCRB | Seres Therapeutics Inc. | 1.33 | -16.38 | -92.49% | |
| PDSB | Pds Biotechnology | 0.81 | 0.05 | 6.89% | |
| COCP | Cocrystal Pharma | 0.97 | 0.07 | 7.55% |
Spero Therapeutics Corporate Events
Spero Therapeutics Appoints William Ho to Board
NeutralOn November 9, 2026, Patrick Vink notified Spero Therapeutics’ board that he would resign as a Class II director and from committee and subsidiary-director roles, effective November 10. The company said the resignation was not due to any dispute or d...
Spero Therapeutics announces planned COO retirement and transition
NeutralOn October 26, 2026, Spero Therapeutics, Inc. announced that Chief Operating Officer Timothy Keutzer will retire from the company effective December 31, 2026, concluding an 11-year tenure marked by leadership and significant contributions. To support...
Spero Therapeutics Launches New Jefferies ATM Equity Program
NeutralOn August 28, 2026, Spero Therapeutics, Inc. entered into a new Open Market Sale Agreement with Jefferies LLC, allowing the company, once its pending universal shelf registration statement becomes effective, to sell up to $100 million of common stock...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
